SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Alexion Pharmaceuticals, Inc. (ALXN) -- Ignore unavailable to you. Want to Upgrade?


To: Jongmans who wrote (29)9/24/1999 12:53:00 AM
From: Larry Liebman  Read Replies (1) | Respond to of 824
 
Piper Jaffray made bullish statements in favor of ALXN. Suggested that success in any of Phase 2 trials could double valuation. Raised initial target from $19 to $25.
Another intriguing biotech. 11 million+ sh. out/$175 million valuation. Products in trials address significant markets.
Worth some due diligence.

P.S. Notice the amount of noise on this thread